Fig. 3From: Efficacy and safety of JAK inhibitors in the treatment of psoriasis and psoriatic arthritis: a systematic review and meta-analysisSubgroup analysis of phase III trials comparing difference in the proportion of patients achieving a (A) 75% improvement in the Psoriasis area and severity index (PASI75) between treatment and placebo and (B) 20% improvement in the American college of Rheumatology composite (ACR20) score between treatment and placeboBack to article page